Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications
Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications May 12, 2020 Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with...
Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2
Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2 Apr 30, 2020 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced its commitment to support the identification of antiviral therapies to...
ERS Genomics and Axxam announce CRISPR-Cas9 license agreement to enhance discovery services
Axxam and ERS Genomics announce CRISPR-Cas9 license agreement to enhance discovery services Apr 2, 2020 Milan (Italy) and Dublin (Ireland) - 2 April 2020 - ERS Genomics Limited (“ERS Genomics”), which was formed to provide broad access to the foundational CRISPR-Cas9...
Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms
Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms Jan 14, 2020 Milan (Italy) and Leiden (Netherlands) - 14 January 2019 - Axxam, the leading drug discovery company with expertise in early phase discovery biology, and ZoBio,...
Dr. Thilo Enderle appointed as new Chief Executive Officer of Hit Discovery Constance GmbH
Dr. Thilo Enderle appointed as new Chief Executive Officer of Hit Discovery Constance GmbH Jan 10, 2019 Milan (Italy)/Constance (Germany) - Axxam announces the appointment of Dr. Thilo Enderle as Chief Executive Officer of Hit Discovery Constance (HDC), a joint...
Axxam SpA expands to Denmark; opens office in Copenhagen
Axxam SpA expands to Denmark; opens office in Copenhagen Sep 27, 2018 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds,...
Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain
Axxam SpA is a member of an international consortium for the further development of a promising drug against neuropathic pain Milan (Italy), 20 September 2018 Axxam is proud to announce its participation to a consortium of international partners, held by the Danish...
Axxam SpA is a member of the RESOLUTE consortium
Axxam SpA is a member of the RESOLUTE consortium Milan, 4th July 2018. Axxam is proud to announce its participation to the RESOLUTE (Research empowerment on solute carriers) consortium, a public-private research partnership supported by the Innovative Medicines...
Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio
Acousia Therapeutics Announces €10 Million Series B Financing to Advance its Hearing Loss Portfolio May 14th, 2018 - Milan (Italy) - Axxam is proud to announce that Acousia Therapeutics (Tubingen; Germany), a biotech company participated by Axxam and focused to...
Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases
Axxam S.p.A. collaborates with GenSight Biologics S.A. to support Clinical Trials of an optogenetic-based gene therapy drug for sight-threatening diseases April 24th 2018 - Milan (Italy) - Axxam S.p.A. announced today a collaboration with GenSight Biologics S.A. in...